Back to Authors

Sexton, Rachel

https://orcid.org/0000-0002-0008-9629

A5103071835 | I4210101190

Mayo Clinic

SWOG Statistical Center, Seattle, WA

Citations 2

P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 855-856

10.1097/01.hs9.0000846728.05693.f8

SWOG 1211: A randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM).

Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS8624-TPS8624

10.1200/jco.2014.32.15_suppl.tps8624